Diclofenac / GLUT1 Cancer Research Results

DFC, Diclofenac: Click to Expand ⟱
Features:
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) commonly used to treat pain, inflammation, and fever.

Diclofenac — a synthetic phenylacetic-acid derivative and nonsteroidal anti-inflammatory drug used clinically for analgesic, anti-inflammatory, and antipyretic effects. It is a nonselective cyclooxygenase inhibitor with moderately greater functional inhibition of COX-2 than COX-1. Standard abbreviations include DCF, DIC, and Dicl. Diclofenac is approved in oral, topical, ophthalmic, rectal, and injectable formulations for non-cancer indications; its proposed anticancer use is drug repurposing and remains investigational.

Primary mechanisms (ranked):

  1. Inhibition of COX-2 and COX-1, reducing prostaglandin E2 production and downstream inflammatory, angiogenic, immunosuppressive, and tumor-promoting signalling.
  2. Suppression of MYC-dependent glucose metabolism, including reduced glucose uptake, glycolytic flux, lactate production, and expression of glycolysis-associated proteins.
  3. Disruption of tumor lactate handling through context-dependent inhibition of monocarboxylate transport and lactate dehydrogenase activity, potentially increasing intracellular metabolic stress and limiting extracellular acidification.
  4. Inhibition of angiogenesis through reduced VEGF expression and tumor vascularization.
  5. Microtubule destabilization, defective mitotic-spindle assembly, G2/M arrest, and mitotic cell death at sufficiently high concentrations.
  6. Mitochondrial dysfunction and ROS accumulation, causing loss of mitochondrial membrane potential and intrinsic apoptosis; this mechanism overlaps with diclofenac toxicity in normal hepatic and cardiac cells.
  7. Context-dependent chemosensitization and radiosensitization through suppression of prostaglandin signalling, tumor metabolism, angiogenesis, and lactate-associated antioxidant capacity.

Bioavailability / PK relevance: Oral diclofenac is extensively absorbed but undergoes substantial first-pass metabolism, producing approximately 50–55% systemic bioavailability. It reaches peak plasma concentration in roughly 2–3 hours, is more than 99% albumin-bound, and has a terminal plasma half-life of approximately 2 hours. Metabolism is primarily hepatic through CYP2C9, with additional CYP2C8, CYP3A4, and UGT2B7 contributions. High protein binding, short systemic exposure, and dose-limiting cardiovascular, gastrointestinal, renal, and hepatic toxicity constrain sustained anticancer exposure. Topical formulations provide high local tissue exposure but substantially lower systemic exposure.

In-vitro vs systemic exposure relevance: Many direct antiproliferative, mitochondrial, ROS, and microtubule effects are reported at approximately 50–500 µM and frequently exceed the sustained unbound concentrations achievable with standard oral dosing. Effects on COX/PGE2 signalling, MYC, lactate metabolism, angiogenesis, or treatment sensitization may occur at lower or intermittently achievable concentrations, but their dependence on tumor type, formulation, exposure duration, and protein content is substantial. High-concentration cytotoxic findings should not be interpreted as evidence that conventional analgesic dosing will directly kill tumors.

Clinical evidence status: Established approved NSAID for pain and inflammatory disorders; preclinical-to-early-human evidence for oncology repurposing. Animal studies and tumor-cell studies support metabolic, antiangiogenic, and cytotoxic activity. Human oncology evidence consists mainly of topical treatment studies in actinic keratosis, perioperative or supportive-care investigations, biomarker studies, and small or ongoing trials. A phase II study is evaluating systemic diclofenac in non-small-cell lung cancer, but diclofenac is not an approved systemic anticancer therapy and there is no established survival benefit from randomized oncology trials.


Diclofenac Mechanistic Profile

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 COX and PGE2 signalling COX-2 activity ↓
PGE2 ↓
EP receptor signalling ↓		 Protective prostaglandins ↓ R–G Inflammatory and tumor-promoting signalling ↓ Core pharmacological mechanism. May reduce proliferation, angiogenesis, invasion, and immunosuppression, but normal-cell COX inhibition contributes to gastrointestinal, renal, and cardiovascular toxicity.
2 MYC and glucose metabolism MYC ↓
Glucose uptake ↓
Glycolysis ↓
Lactate production ↓		 Metabolic effects ↔ or ↓ (context-dependent) G Tumor bioenergetic capacity and proliferation ↓ Observed in melanoma, leukemia, carcinoma, glioma, and triple-negative breast-cancer models. Magnitude depends on dose and exposure duration.
3 Lactate transport and extracellular acidification MCT-dependent lactate transport ↓
LDHA activity ↓
Extracellular lactate ↓
Acidification ↓		 Lactate transport ↓ (context-dependent) R–G Metabolic stress ↑ and acidic tumor microenvironment ↓ Direct MCT4 inhibition by diclofenac remains model- and assay-dependent. Reduced lactate production through MYC and LDHA modulation may be equally or more important.
4 VEGF and angiogenesis VEGF ↓
Vascularization ↓
Endothelial recruitment ↓		 Angiogenic repair ↓ (context-dependent) G Tumor perfusion and growth ↓ Supported mainly by animal tumor models. Effects may derive from COX-2/PGE2 inhibition and altered tumor metabolism.
5 Microtubules and mitotic spindle Microtubule stability ↓
Spindle defects ↑
G2/M arrest ↑		 Mitotic injury ↑ (high concentration only) R–G Mitotic catastrophe and cell death ↑ COX-independent mechanism demonstrated in experimental cancer models, generally at concentrations above routine unbound clinical exposure.
6 Mitochondrial ROS and intrinsic apoptosis Mitochondrial ROS ↑
Membrane potential ↓
Cytochrome c release ↑
Caspase signalling ↑		 Hepatocyte and cardiomyocyte ROS ↑
Mitochondrial injury ↑		 R–G Apoptosis ↑ Potential anticancer leverage overlaps directly with recognized organ toxicity. Reactive metabolites and mitochondrial hydrogen peroxide are important in normal-cell injury.
7 NRF2 antioxidant response NRF2 response ↑ or overwhelmed (dose-dependent) NRF2 stress response ↑ R–G Adaptive antioxidant defence or oxidative death Secondary mechanism. NRF2 activation may protect cells at moderate stress, whereas severe mitochondrial oxidative injury can exceed antioxidant capacity.
8 PI3K AKT and MAPK survival signalling AKT phosphorylation ↓
ERK signalling ↓ or mixed
p38 and JNK stress signalling ↑		 Stress kinase signalling ↑ (context-dependent) R–G Survival signalling ↓ and apoptosis ↑ Reported in selected esophageal, neuroblastoma, and other experimental models; not established as a universal direct target.
9 Radiosensitization and chemosensitization Treatment sensitivity ↑ (context-dependent)
Lactate-mediated ROS buffering ↓		 Normal-tissue injury ↔ or ↑ G Response to radiation or chemotherapy ↑ Preclinical and limited translational evidence. Potential interaction with pemetrexed and other cytotoxic agents may increase renal, gastrointestinal, or marrow toxicity.
10 Clinical Translation Constraint Sustained free-drug exposure limited GI bleeding ↑
Cardiovascular thrombosis ↑
Renal injury ↑
Hepatotoxicity ↑		 G Therapeutic window narrowed Approximately 55% oral bioavailability, greater than 99% protein binding, short half-life, first-pass metabolism, CYP2C9 interactions, and systemic NSAID toxicity limit chronic high-dose oncology use. Local or reformulated delivery may improve exposure but remains investigational.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr
GLUT1, Glucose Transporter 1: Click to Expand ⟱
Source:
Type: protein
Also known as SLC2A1
An important hallmark in cancer cells is the increase in glucose uptake. GLUT1 is an important target in cancer treatment because cancer cells upregulate GLUT1, a membrane protein that facilitates the basal uptake of glucose in most cell types, to ensure the flux of sugar into metabolic pathways.
GLUT1 is a member of the facilitated glucose transporter family and is widely expressed in various tissues, including red blood cells, brain, and cancer cells.
GLUT1 has been shown to be overexpressed in many types of tumors, including breast, lung, and colon cancer. This overexpression may contribute to the development and progression of cancer by promoting glucose uptake and energy production in cancer cells.
GLUT1 is a protein that facilitates the transport of glucose across cell membranes. GLUT1 plays a role in the regulation of glucose metabolism in diabetes.
GLUT1 plays a role in the regulation of glucose metabolism in diabetes.
GLUT1 is also known to be involved in the Warburg effect.
GLUTs are expressed 10–12-fold higher in cancer cells than in healthy tissues, especially in highly proliferative and malignant tumors.

Downregulators:
-Resveratrol: associated with reduced GLUT1 expression.
-Curcumin: downregulate GLUT1 in various cancer cell lines
-Quercetin: downregulating the expression and function of GLUT1.
-EGCG: suppress GLUT1 expression
-Berberine: linked to decreased expression or activity of GLUT1.
Scientific Papers found: Click to Expand⟱
6703- DFC,    Molecular docking of anti-inflammatory drug diclofenac with metabolic targets: Potential applications in cancer therapeutics.
- Analysis, Var, NA
*Inflam?, *COX1↓, *COX2↓, GLUT1↓, MCT4↓, LDHA↓, ABCG2↓, MDM2↓, MRP1/ABCC1↓, SOD2↓, Myc↓, β-catenin/ZEB1↓, VEGF↓, IKKα↓, cJun↓, E2Fs↓,
6693- DFC,    New aspects of an old drug--diclofenac targets MYC and glucose metabolism in tumor cells
- vitro+vivo, Var, NA
Myc↓, GLUT1↓, LDHA↓, MCT1↓, GlucoseCon↓, Glycolysis↓,
6691- DFC,    Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway
- in-vitro, Melanoma, NA - in-vitro, BC, MDA-MB-231 - in-vitro, BC, HCC1937 - in-vitro, BC, MCF7
Glycolysis↓, Apoptosis↑, cMyc↓, GLUT1↓, TumCP↓, HK2↓, TumCP↓,
6688- DFC,    New Aspects of an Old Drug – Diclofenac Targets MYC and Glucose Metabolism in Tumor Cells
- in-vivo, lymphoma, U937
AntiCan↑, COX2↓, Myc↓, GLUT1↓, LDHA↓, MCT1↓, GlucoseCon↓, lactateProd↓, TumCP↓, other∅, toxicity↝,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

SOD2↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

cMyc↓, 1,   GlucoseCon↓, 2,   Glycolysis↓, 2,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 3,   MCT4↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   MCT1↓, 2,   MDM2↓, 1,   Myc↓, 3,  

Transcription & Epigenetics(tgid=7) ⓘ

cJun↓, 1,   other∅, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

E2Fs↓, 1,  

Migration(tgid=13) ⓘ

TumCP↓, 3,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 4,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 1,   IKKα↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   MRP1/ABCC1↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Myc↓, 3,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   toxicity↝, 1,  
Total Targets: 26

Pathway results for Effect on Normal Cells:


Immune & Inflammatory Signaling(tgid=16) ⓘ

COX1↓, 1,   COX2↓, 1,   Inflam?, 1,  
Total Targets: 3

Scientific Paper Hit Count for: GLUT1, Glucose Transporter 1
4 Diclofenac
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:200  Target#:566  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page